Autolus gets FDA RMAT designation for obe-cel in lupus
Autolus Therapeutics says FDA has granted RMAT designation to obe-cel for systemic lupus erythematosus and lupus nephritis. Enrollment in LUMINA, its pivotal Phase 2 study in refractory lupus nephritis, is ongoing.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.